Latest Corporate News
BioMarin Announces $4.8 Billion Acquisition of Amicus Therapeutics
BioMarin Pharmaceutical is acquiring Amicus Therapeutics for $4.8 billion at $14.50 per share, a 30% premium, boosting Amicus stock 30.03%. The deal, BioMarin's second major buyout this year, targets rare disease treatments and is expected to close in Q2 2026.
This strengthens BioMarin's portfolio in innovative therapies for rare diseases.
Jacobio Pharma Signs Global License Deal with AstraZeneca for Pan-KRAS Inhibitor
Jacobio Pharma entered an exclusive global license agreement with AstraZeneca for JAB-23E73, receiving $100M upfront and up to $1.915B in milestones plus royalties outside China. AstraZeneca gains rights outside China while partnering on development in China.
The deal accelerates global oncology innovation for KRAS-mutated cancers.
Skydance Media Completes Merger with Paramount Global
Skydance Media finalized its merger with Paramount Global on August 7, 2025, after regulatory approvals including from FCC and EC. The $4.75B all-stock deal includes $1.5B capital addition and Oracle cloud contract talks.
It integrates assets like CBS, Paramount Pictures, and BET.
2025 Sees Resurgence of Megamergers with 63 Deals Over $10B
Global M&A activity rebounded in 2025 with 63 megadeals valued at $10 billion or more through late November. This marks the return of large-scale corporate consolidations after prior slowdowns.
Analysts review 2025 trends looking ahead to 2026.
Hyundai Motor Showcases WFP Partnership with IONIQ 5 EVs for Humanitarian Aid
Hyundai released films highlighting its WFP collaboration, deploying IONIQ 5 EVs and solar systems across 12 countries. The initiative saves $522K annually and supports sustainable aid operations.
It aligns with Hyundai's 'Progress for Humanity' vision.